Business Wire

HCL and UNLEASH Partner to Develop Solutions for Aquatic Ecosystem Conservation

20.5.2022 18:59:00 EEST | Business Wire | Press release

Share

HCL Group and UNLEASH, a global innovation program for the UN Sustainable Development Goals (SDGs), announced a year-long collaboration to mobilize youth and develop innovative solutions to promote aquatic ecosystem conservation. These solutions will aim to tackle challenges from Source (mountains & glaciers) to Sink (oceans and seas) and their links to terrestrial ecosystems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220520005178/en/

Nature and ocean conservation play a critical role in our survival. Terrestrial and aquatic ecosystems provide us with food, water, oxygen, energy, and medicines. They regulate our climate, provide pollination to crops, and reduce the impact of natural hazards.

Despite the vital importance of our planet’s ecosystems, we are experiencing a human-caused deterioration of our natural habitats: human activity has altered almost 75% of the Earth’s terrestrial surface, squeezing wildlife and nature into an ever-smaller corner.1 Furthermore, ocean heat is at record levels and every year up to 12 million metric tonnes of plastic enter the ocean, damaging ecosystems around the world. Without maintaining healthy and biodiverse terrestrial and aquatic ecosystems, the progress on the remaining United Nations’ SDGs is at critical risk.

To tackle such challenges, UNLEASH and HCL will collaborate to establish a year of youth-led action. Specifically, the partnership will allow youth to develop solutions encompassing SDG 14 (Life below water) and SDG 15 (Life on land), and explore synergies with other SDGs as well. During the process, they will be guided by industry experts and receive hands-on support to ensure that solutions are relatable to the context and feasible in practice.

HCL Group with its large presence in business through HCL Technologies, HCL Infosystems and HCL Healthcare; and its social development organizations including the philanthropic Shiv Nadar Foundation and The Habitats Trust, and its CSR arm – HCL Foundation, has been tackling real on-ground issues related to the SDGs. The Group with its breadth of experience across different sectors and its holistic and powerful sustainability charter is the perfect partner for UNLEASH to successfully push its SDGs innovation efforts.

“Innovation, entrepreneurship, humanity and a people-centric culture are part of HCL’s core, and it is important to us that our progress is reflected in the development of a better world. Our various entities have already been driving important projects to help create a positive impact for the people and the planet. HCL’s collaboration with UNLEASH in bringing innovation to the SDGs, and specifically to the preservation of nature and ocean conservation is an essential step in our overall sustainability efforts”, said Roshni Nadar Malhotra, CEO of HCL, Chairperson of HCL Technologies, Trustee of Shiv Nadar Foundation & Founder of The Habitats Trust.

With HCL’s continuous support on the thematic track From Source to Sink, UNLEASH Talents will have the opportunity to work on localized challenges through joining an UNLEASH Hack at the Shiv Nadar University, Delhi NCR (part of the HCL Group). Earlier this year, UNLEASH Talents participated in three other UNLEASH Hacks related to this theme, exploring challenges of water ecosystems from the Mediterranean, the Danube, Haiti and Hawaii and defining solutions that can drive positive local impact on those regions. The partnership will help scale an existing early-stage solution in the biodiversity space through enrolment in an incubation program, UNLEASH Plus. Thematic insight sessions will be organized throughout 2022, providing inspiration and key learnings on the essence of the theme. These year-long efforts will culminate in the Global Innovation Lab in India that will witness a gathering of 1000+ talented youth for a week long innovation process and help them develop solutions for Indian and global challenges within aquatic and terrestrial ecosystem conservation. The best solutions from the Lab will take home grant prizes to kick-start implementation of the developed solutions. Through the course of this partnership, HCL will enable access to its celebrated business leaders, technical experts, and faculty and academicians of global repute to serve as facilitators, mentors and experts that will help participants across the various programs to develop innovative solutions.

The partnership enables UNLEASH to dive deep into SDG14 and SDG15, and truly establish a community of changemakers, working with nature challenges.

“HCL’s journey in innovation and development is an inspiration for the entire UNLEASH Community. We are very grateful for their partnership on an important matter such as the aquatic conservation of our planet and finding solutions for its preservation through our different programs during the course of this year”, said UNLEASH Chairman Flemming Besenbacher.

About HCL Group

Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies –HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.5 billion with more than 209,000 employees operating across 52 countries.

The Group also includes one of India’s most prolific philanthropic foundations – the Shiv Nadar Foundation. Established in 1994, the Foundation is committed to the creation of a more equitable, merit-based society by empowering individuals through transformational education. Over the last 27 years, it has invested over US$1billion in seven landmark institutions and initiatives across education and art. The Habitats Trust, also a philanthropic Foundation within the HCL Group, specifically works towards protecting natural habitats and their indigenous species of flora and fauna. Established in 2018, the young foundation is undertaking important initiatives that will help secure a positive future for wild species and their habitats.

HCL Foundation, the Corporate Social Responsibility arm of HCL, has instituted flagship programs and initiatives to contribute towards SDGs. Its work is helping bring about lasting positive impact on the people and planet, through long-term sustainable programs, and ensure equitable access, opportunities, and holistic development for all.

For further information, visit www.hcl.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For any queries or information, please contact:
Sadaf Khan | Sadaf-k@hcl.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye